Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weiner, W. J.
Right arrow Articles by Klawans, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiner, W. J.
Right arrow Articles by Klawans, H. L.
NEUROLOGY 1979;29:1622-1625
© 1979 American Academy of Neurology

Dopaminergic antagonism of L-5-hydroxytryptophan-induced myoclonic jumping behavior

William J. Weiner, M.D., Paul M. Carvey, M.S., Paul A. Nausieda, M.D. and Harold L. Klawans, M.D.

From the Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago.

We studied the effect of dopamine agonists (levodopa, apomorphine, lergotrile, and M-7 [2(dimethylamino)5,6-dihydroxytetralin] on myoclonic jumping behavior in young male guinea pigs. All these agents had a significant antagonistic effect on the frequency of this serotonin-mediated behavior. The duration of the antagonism corresponded in all cases to the duration of stereotyped chewing behavior induced by these agents alone. The dopamine antagonist haloperidol potentiated jumping behavior. Therefore myoclonic jumping behavior is influenced by dopaminergic mechanisms, and this behavior may be the result of interaction between dopaminergic and serotonergic activity. The role of dopaminergic mechanisms in human myoclonic disorders needs further clarification.

This work was supported in part by a grant from the United Parkinson Foundation and the Boothroyd Foundation, Chicago, Illinois.

Presented in part at the thirty-first annual meeting of the American Academy of Neurology, Chicago, IL, April 1979.

Address reprint requests to Dr. Weiner, Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, 1725 West Harrison Street, Chicago, IL 60612.

Accepted for publication May 8, 1979.




This article has been cited by other articles:


Home page
J PsychopharmacolHome page
P.L. Gray, D. Dawbarn, and P.V. Taberner
Alterations in dopamine and 5-hydroxytryptamine (5-HT) function during barbiturate dependence and withdrawal in mice
J Psychopharmacol, January 1, 1987; 1(2): 101 - 108.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1979 by AAN Enterprises, Inc.